 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | L-pampo / CHA Vaccine Institute
Journal, IO biomarker: Comparative network-based analysis of toll-like receptor agonist, L-pampo signaling pathways in immune and cancer cells. (Pubmed Central) - Jul 31, 2024
This signal flow may further sensitize prostate cancer to L-pampo due to its high basal expression level of OXPHOS and ROS. Our computational approaches can be applied for inferring underlying molecular mechanisms from complex gene expression profiles.
- L-pampo / CHA Vaccine Institute
L-pampo (Section 28) - Mar 5, 2024 - Abstract #AACR2024AACR_5479;
To compare the anti-tumor efficacy of L-pampo and conventional cytotoxic chemotherapy, we treated tumor-bearing mice with FOLFOX or paclitaxel as SoC regimen, respectively... This study suggests that L-pampo, a novel TLR2/3 agonist, can be a potent anti-tumor agent, improving the anti-tumor efficacy of ICIs in cold tumors with enhanced anti-tumor immunity and minimal toxicities than conventional chemotherapies.
- | L-pampo / CHA Vaccine Institute
Journal, IO biomarker: L-Pampo (Pubmed Central) - Aug 12, 2023
This study suggests that L-pampo, a novel TLR2/3 agonist, can be a potent anti-tumor agent, improving the anti-tumor efficacy of ICIs in cold tumors with enhanced anti-tumor immunity and minimal toxicities than conventional chemotherapies. Moreover, the combination of L-pampo
- | L-pampo / CHA Vaccine Institute
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. (Pubmed Central) - Jul 6, 2022
Moreover, the combination of L-pampo Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade.
- | L-pampo / CHA Vaccine Institute
Journal: COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity. (Pubmed Central) - Sep 29, 2021
Furthermore, in the ferret model, SARS-CoV-2 antigens with L-pampo elicited nAb response and antigen-specific cellular immune response against SARS-CoV-2, resulting in substantially decreased viral load in their nasal wash. Our study suggests that SARS-CoV-2 antigens formulated with TLR agonists, L-pampo, can be a potent subunit vaccine to promote sufficient protective immunity against SARS-CoV-2.
- L-pampo / CHA Vaccine Institute
[VIRTUAL] Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2319;
Our study suggests that SARS-CoV-2 antigens formulated with TLR agonists, L-pampo, can be a potent subunit vaccine to promote sufficient protective immunity against SARS-CoV-2. Overall, our study demonstrated that intratumoral immunotherapy with L-pampo elicits strong anti-tumor immunity within the tumor microenvironment and strengthens the efficacy of immune checkpoint blockade.